Brief: Poxel Regains Imeglimin Rights From Metavant

Poxel SA

14/01/2021 16:57

Jan 14 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL REGAINS IMEGLIMIN RIGHTS FROM METAVANT
    * PARTNERSHIP AGREEMENT WITH METAVANT WILL BE TERMINATED,
EFFECTIVE JANUARY 31, 2021
    * METAVANT IS NOT ENTITLED TO ANY PAYMENT FROM POXEL AS PART
OF
RETURN OF PROGRAM
    * METAVANT WILL RETURN ALL RIGHTS TO IMEGLIMIN TO POXEL, AS
WELL
AS ALL DATA, MATERIALS, AND INFORMATION, INCLUDING FDA
REGULATORY FILINGS, RELATED TO PROGRAM
    * A NEW DRUG APPLICATION IN JAPAN (J-NDA) IS CURRENTLY
ADVANCING
THROUGH REGULATORY REVIEW WITH OUR PARTNER SUMITOMO DAINIPPON
PHARMA- POXEL CEO
    * TARGET PRODUCT LAUNCH IS ANTICIPATED IN FISCAL YEAR 2021 -
CEO

Source text for Eikon:  ID:nBw7DTy8Wa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))